**Reviewer’s Comments**



 **The association of Epstein-Barr Virus Antibodies with Rheumatoid ArthritisamongYemeni patients in Sana'a city**

**Abstract**

**Background and objective:** Rheumatoid arthritis (RA) is a chronic autoimmune disease that isassociated with progressive disability, systemic complications and early death. Etiology of RA is unknown. It is assumed that environmental factors initiate RA development ingenetically susceptible individuals.Epstein-Barr Virus(EBV) stimulates polyclonal B cell activation and has been suggested to play a role in RA pathogenesis. Our study aimed tostudythe association between EBV and RA.

**Methods:** One hundred and sixty subjects were enrolled in the study.Eighty individuals were clinically diagnosed to have RA and confirmed by anti-CCP3 test.The remaining 80 individuals were healthy controls matched for age and sex. Serum IgG and IgM antibodies against EBV viral capsid antigen(VCA) weretested by anenzyme-linked immunosorbent assay (ELISA).

**Results:** The crude prevalence rate of EBV-VCA IgM antibodies among patients was (21.2%)while in healthy individuals was (8.7%) with significant OR equals to 2.8 times for RA patient's. The female prevalence rate of EBV-VCA IgM antibodies was (21.8%) higher than of male(18.7%). Moreover, the crude prevalence rate of EBV-VCA IgG antibodies for RA patients was (91.3%) while in healthy individuals was(76.3%)with significant OR equals to 3.2 times for RA patients'. The female prevalence rate ofEBV-VCA IgGantibodies was (95.3%) higher than of male(75%).

**Conclusion:**EBV-VCA IgGand IgM antibodiestiters were elevated in RA patients than in healthy controls. However, the causative relationship between EBV and RA is complex and involvesdifferent mechanisms.

**Key words**: Anti EBV-VCA IgG antibodies, anti EBV-VCA IgM antibodies, Epstein-Barr Virus, Rheumatoid arthritis, Yemeni.

**1. Introduction**

Rheumatoid arthritis (RA) is a chronic autoimmune disorder which is common among females at an older age.Worldwide prevalence of RA is estimated to be about 0.5%-1%.The cause of RA remains unclear though it has been proposedbyprevious studies that both genetic and environmental factors play an important role in RA pathogenesis1-3.RA genetic susceptibility is carried by HLA-DRB1\* alleles containing the QK/RRAA or RRRAA motif in their third hypervariable region. This motif is known as the shared epitope4. It is associated with low occurrence of T cells specific for EBV gp110, a replicative phase glycoprotein critical for the control of EBV infection5. One environmental trigger may be the Epstein-Barr virus (EBV).

 EBV is a double-stranded DNA herpesvirus that is extremely common worldwide, infecting about 98% of the human populationby the age of 40 years6. It is transmittedthrough saliva.It infects and replicates in epithelial cellsand B cells. EBV then becomes latent within memory B cells andpersists for the lifetime of the host7.It causes acute infectious mononucleosis. It also reported to have association with nasopharyngeal carcinoma, Hodgkin and non-Hodgkin lymphomas, gastric carcinoma, Burkitt lymphoma and other lympho-proliferative disorders in immunocompromised individuals8.

 For long time, EBV has been suspected as a possibleetiology of autoimmune diseases including RAdue to its high prevalence in the population and its lifelonginfection after primary infection9, 10. The association between EBV and RA was first reported by Alspaugh and Tan. They reported that sera from RA patients were reactiveagainst a nuclear antigen in EBV-transformed lymphocytes11. Association between RA pathogenesis and EBV has been linked to molecular mimicry. Several EBV antigens share similarities with self-antigens; more specifically, glycine/alanine repeats in EBNA-1 resemble synovial proteins.Antibodies againstthis repeat cross-react with a 62kD protein in RA, but not in normal synovium12, 13.EBV DNA loads are higherin mononuclear cells isolated from active RA patients compared to healthyseropositive individuals as well as EBV serology. Furthermore,antibodies directed against cyclic citrullinated peptides (ACPA) whichare used as confirmatory test for RA diagnosis, were found to react with acitrullinated sequence of Epstein-Barr nuclear antigen-1 (EBNA-1),supporting the association between EBV and RA14. Ourstudy aimed to investigate the association between EBV and RA via measuring EBV-VCA IgM and IgG in RA patients compared with healthy controls.

**2. Subjects and methods**

This study is a case-control study conducted from October 2014 to October 2015. A total number of 160 individuals were included in the study. Eighty persons were clinically diagnosed with RA and confirmed by measuring anti-CCP3. The other 80 were healthy individuals used as controls. A full history from each RA case and healthy control was recorded on a predesigned questionnaire. The study was carried out at Al-Thawra Modern General Hospital and National Center of Central Public Health Laboratories, in Sana'a city, Yemen. Patients with other autoimmune diseases,infectious mononucleosis, Hodgkin's lymphoma, Burkitt's lymphoma, nasopharyngeal carcinoma, or with HIV were excluded from the study.

Five ml of venous blood was collected from each individual into plain vacationer tubes. The specimens were allowed to clot at room temperature and centrifuged at 3500 rpm for five minutes. Serum was separated from each sample into Eppendorf tubes and stored at -20°C until tested.

EBV virologic assays to measure IgG and IgM viral capsid antigen (VCA) were performed using NovaLisaEBV ELISA kits provided by (NOVA TEC, Dietzenbach, Germany). The commercially ELISA test for anti-CCP3 was carried out according to the manufactures instructions (INOVA Diagnostics Kits, San Diego, CA-USA). Statistical analysis of data was performed using the Epi Info statistical program version 6 (CDC, Atlanta, USA).

**3. Results**

Table 1 shows the characteristics of RA patients and healthy controls. Out of 80 RA cases, 64 (80%) were females while 16 (20%) were males. Their age ranged from 20 to 80 years with mean age 42.3±16.3 years old. Likewise, the control group involved 64 (80%) females and 16 (20%) males. Their age ranged from 20 to 80 years with mean age 39.6±11.2 years old. Most of the cases and controls were at the age group of≥50 years old.

 Table 2 shows the prevalence rate of EBV-VCA IgM antibodies in different sex and age groups for RA patients and healthy controls. EBV-VCA IgM antibodies among RA females, 14 (21.8%), were higher than that of RA males, 3 (18.7%), with an OR equals to 2.7 times for females than males whereas in control females, 6 (9%), and males, 1(6%). As regard to the age, the serum EBV-VCA IgM antibodies in RA patients were highest at the age group of 40-49, years in which the rate was (30%), followed by the age group of ≥50 years (25%), then the age group of 30-39 years (18.7%), and finally the age group of 20-29 years (13.6%). Among the controls, corresponding numbers were 1(10%), 3(9.3%), 2(12.5%), and 1(4%), respectively. When we compared the crude prevalence rate of EBV IgM antibodies among cases and controls, we found that the crude prevalence rate among RA patients was 21.2% while among controls was 8.7%. OR of EBV infection for RA cases was 2.8 times, and this association was ranged from 1.01 up to 8.1, with significant χ2 (4.9) and statistically *p* equals to 0.02.

Table 3 demonstrates the prevalence rate of EBV-VCA IgG antibodies in different sex and age groupsof RA patients and healthy controls. The EBV-VCA IgG antibodies among females, 61 (95.3%), were higher than that of males, 12 (75%), among cases with an OR equal to 5.2 times for females than maleswhereas, in control females, 51(79.6%),and males, 10 (62.5%). As regard to the age, the serum EBV-VCA IgG antibodies were highest at the age group of ≥50 years old, in which the rate was (100%), followed by the age group of 40-49 years (90%), then the age group of 30-39 years (87.5%), and finally the age group of 20-29 years (81.8%).Among the control, corresponding numbers were 28(87.5%), 7(70%), 12(75%), and 14(63.6%), respectively. When we compared the crude prevalence rate of EBVIgG antibodies among cases and controls we found that the crude prevalence rate among RA patients was 91.3% while among controls, was 76.3%. OR of contract EBV infection for RA cases was 3.2 times, and this association was ranged from 1.2 up to 9.2, with significant χ2(6.6) and statistically *p* equal to 0.01.

**4. Discussion**

RA is a systemic autoimmune disease of unknown etiology. Both genetic and environmental factorsare suggested to contribute to RA pathogenesis 1, 15. Epstein-Barr virus was proposed as an environmental triggerof RA.It causes massive polyclonal expansion of resting lymphocytes and becomes latent within memory B cells for the lifetime of the host16. Thisstudy aimed to investigate the association between EBV and RA via measuring EBV-VCA IgM and IgG in RA patients compared with healthy controls.

 Our study showed a highly significant rate and associated OR of positive EBV-VCA IgM and IgGin RA patients than in healthy controls. Several studies have shown elevation of EBVantibodies in RA patients than healthy controls14, 17, 18. So far,there is no decisive theory to explain how EBV is involved in RA pathogenesis. However, several representative hypotheses on the possible mechanisms of EBV’s involvement in autoimmune diseases are described19. One mechanism by which EBV can trigger RA is molecular mimicry20. Studies found antibodies against EBV-encodedproteins cross-react with RA-specific proteins7, 11, 21. This finding supports the molecular mimicry hypothesis in RA pathogenesis either by influencing T cell receptor recognition of the HLA ‘shared epitope’ or through production of autoantibodies against joint antigens6. Molecular mimicry between a major EBV epitope and severalautoantigens might contribute to a breakdown of tolerance and autoimmunity in patientswith RA22.

 Another possible mechanism is through autoreactive B cellstheory. It hypothesizes that in patients with certain autoimmune diseases,EBV infects autoreactive B cells leading to autoantibodies production23, 24. Third mechanism is through the mistaken-self theory. EBV-infected B cells together with closely located activated T cells have been demonstrated in the synovial lesions of RA25, 26.

 High titers of EBV antibodies is not attributed to more frequent EBV reactivation in RA patients as a result of immunosuppression therapy. Studies monitored EBV viral load in RA patients under TNF blockers for one to five. EBV load was stable over time, evenwhen TNF blockers were associated with methotrexate27-29.

 In conclusion, high titers of EBV antibodies are associated with RA. However, the causative relationship between EBV and autoimmune diseases is complex and involvesdifferent mechanisms.

**Conclusion**

**Acknowledgments:**

The authors thank physicians and specialists at the Department of Rheumatology at Al-Thawra Modern General Hospital and staff at Virology Department atNational Center of Central Public Health Laboratories for their great help during study performance.

**Conflict of Interest:**

There is no conflict of interest to be declared

**References**

1 McInnes IB, GSchett. The pathogenesis of rheumatoid arthritis, N Engl J Med;2011: 365:2205-2219

2 Myasoedova E, JMDavis, CSCrowson, SEGabriel. Epidemiology of rheumatoid arthritis: Rheumatoid arthritis and mortality, Curr Rheumatol Rep; 2010: 12:379-385.

3 Pedersen M, S Jacobsen, PGarred, HOMadsen, MKlarlund, ASvejgaard, BVPedersen, JWohlfahrt, MFrisch. Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: A nationwide case-control study in denmark, Arthritis Rheum; 2007: 56:1446-1453.

4 Winchester R, EDwyer, SRose. The genetic basis of rheumatoid arthritis. The shared epitope hypothesis, Rheum Dis Clin North Am; 1992: 18:761-783

5 Arleevskaya MI, OAKravtsova, J Lemerle, YRenaudineau, APTsibulkin. How rheumatoid arthritis can result from provocation of the immune system by microorganisms and viruses, Front Microbiol; 2016: 7:1296.

6 Costenbader KH, Karlson EW. Epstein-barr virus and rheumatoid arthritis: Is there a link? Arthritis Res Ther; 2006: 8:204.

7 Niller HH, Wolf H, Ay E, Minarovits J. Epigenetic dysregulation of epstein-barr virus latency and development of autoimmune disease, Adv Exp Med Biol; 2011: 711:82-102

8 Butel J. General properties of viruses. In: KC C, ed. Jawetz, melnick, and adelberg's medical microbiology. New York: McGraw-Hill Education; 2013:407–415.

9 Adtani P, Malathi N. Epstein-barr virus and its association with rheumatoid arthritis and oral lichen planus, J Oral Maxillofac Pathol; 2015: 19:282-285

10 Mahabadi M, Faghihiloo E, Alishiri GH, Ataee MH, Ataee RA. Detection of epstein-barr virus in synovial fluid of rheumatoid arthritis patients, Electron Physician: 2016: 8:2181-2186

11 Aslpaugh MA, Tan EM. Serum antibody in rheumatoid arthritis reactive with a cell-associated antigen. Demonstration by precipitation and immunofluorescence, Arthritis Rheum, 1976: 19:711-719.

12 Toussirot E, Roudier J. Pathophysiological links between rheumatoid arthritis and the epstein-barr virus: An update, Joint Bone Spine; 2007: 74:418-426.

13 Baboonian C, Halliday D, Venables PJ, Pawlowski T, Millman G, Maini RN. Antibodies in rheumatoid arthritis react specifically with the glycine alanine repeat sequence of epstein-barr nuclear antigen-1, Rheumatol Int; 1989: 9:161-166.

14 Westergaard MW, Draborg AH, Troelsen L, Jacobsen S, Houen G. Isotypes of epstein-barr virus antibodies in rheumatoid arthritis: Association with rheumatoid factors and citrulline-dependent antibodies, Biomed Res Int; 2015: 2015:472174.

15 Birch JT, Jr., Bhattacharya S. Emerging trends in diagnosis and treatment of rheumatoid arthritis, Prim Care; 2010: 37:779-792.

16 Balandraud N, Roudier J, Roudier C. Epstein-barr virus and rheumatoid arthritis, Autoimmun Rev; 2004: 3:362-367.

17 Alderzi AR AM, Alhadithi HS. Epstein–barr virus antibodies in rheumatoid artheritis iraqi patients, J Fac Med Baghdad; 2013: 55:358-361

18 Ferrell PB, Aitcheson CT, Pearson GR, Tan EM. Seroepidemiological study of relationships between epstein-barr virus and rheumatoid arthritis, J Clin Invest; 1981: 67:681-687.

19 Shigeyoshi Fujiwara MT. Epstein-barr virus and autoimmune diseases, Clinical and Experimental Neuroimmunology; 2015: 6:38-48.

20 Cusick MF, Libbey JE, Fujinami RS. Molecular mimicry as a mechanism of autoimmune disease, Clin Rev Allergy Immunol; 2012: 42:102-111.

21 Alspaugh MA, Jensen FC, Rabin H, Tan EM. Lymphocytes transformed by epstein-barr virus. Induction of nuclear antigen reactive with antibody in rheumatoid arthritis, J Exp Med; 1978: 147:1018-1027.

22 Balandraud NRJ. Epstein-barr virus and rheumatoid arthritis, Joint Bone Spine; 2017: http://dx.doi.org/10.1016/j.jbspin.2017.04.011.

23 Pender MP. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases, Trends Immunol; 2003: 24:584-588.

24 Niller HH, Wolf H, Minarovits J. Regulation and dysregulation of epstein-barr virus latency: Implications for the development of autoimmune diseases, Autoimmunity; 2008: 41:298-328.

25 Scotet E, David-Ameline J, Peyrat MA, Moreau-Aubry A, Pinczon D, Lim A, Even J, Semana G, Berthelot JM, Breathnach R, *et al*. T cell response to epstein-barr virus transactivators in chronic rheumatoid arthritis, J Exp Med; 1996: 184:1791-1800.

26 van Noort JM, Bajramovic JJ, Plomp AC, van Stipdonk MJ. Mistaken self, a novel model that links microbial infections with myelin-directed autoimmunity in multiple sclerosis, J Neuroimmunol; 2000: 105:46-57.

27 Miceli-Richard C, Gestermann N, Amiel C, Sellam J, Ittah M, Pavy S, Urrutia A, Girauld I, Carcelain G, Venet A, *et al*. Effect of methotrexate and anti-tnf on epstein-barr virus t-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies, Arthritis Res Ther; 2009: 11:R77.

28 Balandraud N, G Texier, EMassy, OMuis-Pistor, MMartin, IAuger, MCGuzian, SGuis, TPham, JRoudier. Long term treatment with abatacept or tocilizumab does not increase epstein-barr virus load in patients with rheumatoid arthritis - a three years retrospective study, PLoS One; 2017:12:e0171623.

29 Couderc M, SPayet, CHenquell, JJDubost, M Soubrier. Tnfalpha antagonist therapy does not increase the epstein-barr virus burden in patients with rheumatoid arthritis or ankylosing spondylitis, Joint Bone Spine; 2010: 77:414-417.

**Table 1:** Age and sex of rheumatoid arthritis cases and healthy controls

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable Characteristics** | Cases **(n=80)** | Controls**(n=80)** | Total**(n=160)** |
| **No.** | **%** | **No.** | **%** | **No.** | **%** |
| **Age/ Years** |  |
| 20-29  | 22 | 27.5 | 22 | 27.5 | 44 | 27.5 |
| 30-39  | 16 | 20.0 | 16 | 20.0 | 32 | 20.0 |
| 40-49  | 10 | 12.5 | 10 | 12.5 | 20 | 12.5 |
| ≥50  | 32 | 40.0 | 32 | 40.0 | 64 | 40.0 |
| **Total** | **80** | **100** | **80** | **100** | **160** | **100** |
| Mean/ Years | 42.3 | 39.6 | 39.9 |
| SD/ Years | 16.3 | 11.2 | 14.5 |
| Min./ Years | 20 | 20  | 20  |
| Max./ Years | 80 | 80 | 80 |
| **Sex** |  |
| Females | 64 | 80.0 | 64 | 80.0 | 128 | 80 |
| Males | 16 | 20.0 | 16 | 20.0 | 32 | 20 |
| **Total** | **80** | **100** | **80** | **100** | **160** | **100** |

**Table 2:**Seropositive for EBV-VCA IgM for RA patients and healthy controls

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Age and Sex groups** | **Seropositive for EBV-VCA IgM** | **OR** | **CI** | **χ2** | ***P*** |
| **Case** | **Control** |
| **No.** | **%** | **No.** | **%** |
| **Age/ Years** |  |
| 20-29  | 3 | 13.6 | 1 | 4 | 4 | 0.26-9.0 | 1.1 | 0.29 |
| 30-39  | 3 | 18.7 | 2 | 12.5 | 1.6 | 0.17-16.7 | 0.24 | 0.62 |
| 40-49  | 3 | 30 | 1 | 10 | 3.8 | 0.24-12.1 | 1.25 | 0.26 |
| ≥50  | 8 | 25 | 3 | 9.3 | 3.2 | 0.66-17.5 | 2.74 | 0.09 |
| **Sex** |  |
| Female **(n=64**) | 14 | 21.8 | 6 | 9 | 2.7 | 0.8-8.6 | 3.8 | 0.05 |
| Males **(n=16**) | 3 | 18.7 | 1 | 6 | 3.46 | 0.3-9.8 | 1.14 | 0.28 |
| Crude rate IgM | 17 | 21.2 | 7 | 8.7 | 2.8 | 1.01-8.1 | 4.9 | 0.02 |

**Table 3:**Seropositive for EBV-VCA IgG for RA patients and healthy controls

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Age and Sex groups** | **Case** | **Control** | **OR** | **CI** | **χ2** | ***P*** |
| **No.** | **%** | **No.** | **%** |
| **Age/ Years** |  |
| 20-29  | 18 | 81.8 | 14 | 63.6 | 2.6 | 0.54-13 | 1.8 | 0.17 |
| 30-39  | 14 | 87.5 | 12 | 75 | 2.3 | 0.3-22.7 | 0.82 | 0.36 |
| 40-49  | 9 | 90 | 7 | 70 | 3.86 | 0.24-121 | 1.25 | 0.26 |
| ≥50  | 32 | 100 | 28 | 87.5 | Undefined | 4.2 | 0.03 |
| **Sex** |  |
| Female **(n=64**) | 61 | 95.3 | 51 | 79.6 | 5.2 | 1.28-24.4 | 7.14 | 0.007 |
| Males **(n=16**) | 12 | 75 | 10 | 62.5 | 1.8 | 0.3-10.7 | 0.58 | 0.44 |
| Crude rate IgG | 73 | 91.3 | 61 | 76.3 | 3.25 | 1.2-9.2 | 6.6 | 0.01 |